TJO-002
- Generic Name
- TJO-002
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
Phase 3
Completed
- Conditions
- Primary Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT03419975
- Locations
- 🇰🇷
Chan Yun, Kim, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath